TY - JOUR
T1 - Inverse Associations between Measures of Adiposity and Glycated Albumin in US Adults, NHANES 1999-2004
AU - Sullivan, Valerie K.
AU - Wallace, Amelia S.
AU - Rooney, Mary R.
AU - Zhang, Sui
AU - Fang, Michael
AU - Christenson, Robert H.
AU - Selvin, Elizabeth
N1 - Funding Information:
Authors’ Disclosures or Potential Conflicts of Interest: Upon manuscript submission, all authors completed the author disclosure form. Disclosures and/or potential conflicts of interest: Employment or Leadership: R.H. Christenson, The Journal of Applied Laboratory Medicine, AACC; E. Selvin, Diabetes Care, Diabetologia, American Diabetes Association, American Heart Association. Consultant or Advisory Role: R.H. Christenson, Quidel Medical, Roche Diagnostics, Siemens Healthineers, Beckman Coulter, Sphingotech, Pixcell Medical. Stock Ownership: None declared. Honoraria: E. Selvin receives payments from Wolters Kluwer for chapters and laboratory monographs in UpToDate on measurements of glycemic control and screening tests for type 2 diabetes and received speaker’s honoraria from Novo Nordisk in 2019. R.H. Christenson has received payments from Siemens Healthineers, Roche Diagnostics, Beckman Coulter, Sphingotech GHB, and Quidel Medical. Research Funding: This work was funded by a grant from the Foundation for the National Institutes of Health Biomarkers Consortium to the Johns Hopkins Bloomberg School of Public Health (PI: E. Selvin). The Foundation for the National Institutes of Health received support for this project from Abbott Laboratories, AstraZeneca, Johnson & Johnson, the National Dairy Council, Ortho Clinical Diagnostics, Roche Diagnostics, and Siemens Healthcare Diagnostics. Reagents for the glycated albumin assay were donated by the Asahi Kasei Pharma Corporation. E. Selvin was also supported by NIH/NHLBI grant K24 HL152440. V.K. Sullivan was supported by NIH/NHLBI grant T32 HL007024. A. Wallace, NIH/NHLBI T32 HL007024; M. Rooney, NIH/NHLBI T32 HL007024. Expert Testimony: None declared. Patents: None declared.
Publisher Copyright:
© 2023 American Association for Clinical Chemistry.
PY - 2023/7/1
Y1 - 2023/7/1
N2 - Background: Glycated albumin (GA) is a short-Term measure of glycemic control. Several studies have demonstrated an inverse association between body mass index (BMI) and GA, which may affect its performance as a biomarker of hyperglycemia. We investigated cross-sectional associations between GA and multiple measures of adiposity, and compared its performance as a glycemic biomarker by obesity status, in a nationally representative sample of US adults. Methods: We measured GA in adults from the 1999-2004 National Health and Nutrition Examination Survey. Separately in adults with and without diabetes, we assessed associations of GA with adiposity measures (BMI, waist circumference, trunk fat, total body fat, and fat mass index) in sex-stratified multivariable regression models. We compared sensitivity and specificity of GA to identify elevated hemoglobin A1c (HbA1c), by obesity status. Results: In covariate-Adjusted regression models, all adiposity measures were inversely associated with GA in adults without diabetes (β=-0.48 to-0.22%-point GA per 1 SD adiposity measure; n = 9750) and with diabetes (β=-1.73 to-0.92%-point GA per SD). Comparing adults with vs without obesity, GA exhibited lower sensitivity (43% vs 54%) with equivalent specificity (99%) to detect undiagnosed diabetes (HbA1c ≥ 6.5%). Among adults with diagnosed diabetes (n = 1085), GA performed well to identify above-Target glycemia (HbA1c ≥ 7.0%), with high specificity (>80%) overall but lower sensitivity in those with vs without obesity (81% vs 93%). Conclusions: Inverse associations between GA and adiposity were present in people with and without diabetes. GA is highly specific but may not be sufficiently sensitive for diabetes screening in adults with obesity.
AB - Background: Glycated albumin (GA) is a short-Term measure of glycemic control. Several studies have demonstrated an inverse association between body mass index (BMI) and GA, which may affect its performance as a biomarker of hyperglycemia. We investigated cross-sectional associations between GA and multiple measures of adiposity, and compared its performance as a glycemic biomarker by obesity status, in a nationally representative sample of US adults. Methods: We measured GA in adults from the 1999-2004 National Health and Nutrition Examination Survey. Separately in adults with and without diabetes, we assessed associations of GA with adiposity measures (BMI, waist circumference, trunk fat, total body fat, and fat mass index) in sex-stratified multivariable regression models. We compared sensitivity and specificity of GA to identify elevated hemoglobin A1c (HbA1c), by obesity status. Results: In covariate-Adjusted regression models, all adiposity measures were inversely associated with GA in adults without diabetes (β=-0.48 to-0.22%-point GA per 1 SD adiposity measure; n = 9750) and with diabetes (β=-1.73 to-0.92%-point GA per SD). Comparing adults with vs without obesity, GA exhibited lower sensitivity (43% vs 54%) with equivalent specificity (99%) to detect undiagnosed diabetes (HbA1c ≥ 6.5%). Among adults with diagnosed diabetes (n = 1085), GA performed well to identify above-Target glycemia (HbA1c ≥ 7.0%), with high specificity (>80%) overall but lower sensitivity in those with vs without obesity (81% vs 93%). Conclusions: Inverse associations between GA and adiposity were present in people with and without diabetes. GA is highly specific but may not be sufficiently sensitive for diabetes screening in adults with obesity.
UR - http://www.scopus.com/inward/record.url?scp=85165366286&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85165366286&partnerID=8YFLogxK
U2 - 10.1093/jalm/jfad004
DO - 10.1093/jalm/jfad004
M3 - Article
C2 - 36998214
AN - SCOPUS:85165366286
SN - 2576-9456
VL - 8
SP - 751
EP - 762
JO - The journal of applied laboratory medicine
JF - The journal of applied laboratory medicine
IS - 4
ER -